ArticleJournal of neurology2020
Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease.
Article in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05769972 (Randomized, Single-blind Clinical Trial to Evaluate the Efficacy of Cognitive Rehabilitation Using Inmersive Virtual Reality and Computer-based Cognitive Stimulation Versus Music Therapy on Cognitive Impairment Associated With Movement Disorders), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Single-blind Clinical Trial to Evaluate the Efficacy of Cognitive Rehabilitation Using Inmersive Virtual Reality and Computer-based Cognitive Stimulation Versus Music Therapy on Cognitive Impairment Associated With Movement Disorders
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington's disease.Journal of neurology · 2025Trial
- Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.European journal of nuclear medicine and molecular imaging · 2026Article
- Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Neural and biomarker correlates of the Parkinson's Disease-Cognitive Rating Scale in Huntington's disease.Neuroimage. Reports · 2026Article
- Early Language Impairment as an Integral Part of the Cognitive Phenotype in Huntington's Disease.Annals of clinical and translational neurology · 2025Article
- Cognitive phenotype and neurodegeneration associated with Tau in Huntington's disease.Annals of clinical and translational neurology · 2024Article
- Measuring cognitive impairment and monitoring cognitive decline in Huntington's disease: a comparison of assessment instruments.Journal of neurology · 2023Article
- Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross-sectional study.Brain and behavior · 2021Article
- EEG Functional Connectivity and Cognitive Variables in Premanifest and Manifest Huntington's Disease: EEG Low-Resolution Brain Electromagnetic Tomography (LORETA) Study.Frontiers in physiology · 2020Article
- Structural brain correlates of dementia in Huntington's disease.NeuroImage. Clinical · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
28 authors at 9 institutions in 7 countries.
Funding
Abstract
backgroundCognitive impairment is an essential feature of Huntington's disease (HD) and dementia is a predictable outcome in all patients. However, validated instruments to assess global cognitive performance in the field of HD are lacking.
objectivesWe aimed to explore the utility of the Parkinson's disease-Cognitive Rating Scale (PD-CRS) for the screening of global cognition in HD.
methodsA multicenter cohort of 132 HD patients at different disease stages and 33 matched healthy controls were classified as having preserved cognition, mild cognitive impairment (HD-MCI) or dementia (HD-Dem) according to the Clinical Dementia Rating and Functional Independence Score. The PD-CRS and the Mini-Mental State Examination were administered. Receiver operating characteristic curve analysis was used to determine optimal cutoffs to differentiate patients according to their cognitive status.
resultsA PD-CRS cutoff score ≤ 81/82 was optimal to detect HD-MCI (sensitivity = 93%; specificity = 80%; area under the curve (AUC) = 0.940), and ≤ 63/64 was optimal to detect HD-Dem (sensitivity = 90%; specificity = 87%; AUC = 0.933). MMSE scores failed to show robust psychometric properties in this context. DISCUSSION: The PD-CRS is a valid and reliable instrument to assess global cognition in HD in routine clinical care and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.